Efficacy and safety of SHEN26, a novel oral small molecular RdRp inhibitor for COVID-19 treatment: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial
新型口服小分子RdRp抑制剂SHEN26治疗COVID-19的疗效和安全性：一项多中心、随机、双盲、安慰剂对照的II期临床试验
期刊:Virology Journal
影响因子:3.8
doi:10.1186/s12985-025-02631-y
Bai, Jiangtao; Asakawa, Tetsuya; Yuan, Wenfang; Lin, Yuanlong; Ju, Hao; Xu, Dandan; Yang, Mingming; Li, Shuo; Li, Guanguan; Guo, Deyin; Lu, Hongzhou; Zhang, Xumu
